Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK, United Kingdom

Disclosure(s): GSK: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1101) A Comparative Analysis of Resistance Rates Among Escherichia coli and Klebsiella pneumoniae Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1492) Patient Characteristics Associated with Extended-Spectrum Beta-Lactamase-Producing Uropathogens: Pooled Results from Two Phase 3 Clinical Trials of Gepotidacin for the Treatment of Uncomplicated Urinary Tract Infection
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT